90% of patients, having undergone an Ellansé S and M treatment, had improved, much improved or very much improved results at 12 months. 6 100% of patients, having undergone an Ellansé M treatment, had improved, much improved or very much improved results at 24 months. 6 Innovation for safety and optimal results 1
Ellansé M offers immediate and sustained performance 7
• Efficacy increases notably from 1 to 3 months • Results are maintained for up to 24 months
MEAN GAIS SCORES
3
Mean GAIS score over a 24-month period. The scores increased notably from 1 to 3 months, and the scores were well maintained for up to 24 months.
2.5
2
MEAN GAIS SCORES PHYSICIAN EVALUATION 1 month 3 month 6 month 12 month 24 month 2.14 ± 0.95 2.38 ± 0.77 2.50 ± 0.76 2.45 ± 0.52 2.33 ± 0.50
1.5
1
0.5
Global Aesthetic Improvement Scale (GAIS) 3 = very much improved | 2 = much improved 1 = improved | 0 = no change | -1 = worse
0
1
3
6 MONTHS
12
24
A clinical trial by Bae et al. (2016) evaluated the safety and efficacy of forehead augmentation with Ellansé-M in combination with botulinum toxin Type A (n=58). Efficacy was assessed using physician scores from the GAIS at 1, 3, 6, 12 and 24 months post-treatment.
Investigator Evaluated Global Aesthetic Improvement Scale (GAIS) Ellansé S Ellansé M High efficacy of Ellansé-S and Ellansé-M in nasolabial fold treatment with high safety over a 2 year period 6
Proven Neocollagenesis for regenerative results
2013: 21 months post-injection (rabbit), Type I collagen confirms stable environment and long-term efficacy. 8
3.5%
5,2%
TYPE I COLLAGEN
100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0%
6%
4%
23%
7%
10%
13,8%
20%
20%
50μm
51.7%
50%
62,8%
11% 11%
55%
45%
58%
50%
71%
10%
77%
60%
78%
45%
2015: 13 months post-injection, confirmed collagen production in the human body. PCL microspheres were surrounded with collagen deposition and a mild fibroblastic and histiocytic tissue response (Martin’s Trichrome staining, a collagen staining). 9
44%
41.4%
40% 45%
35%
35%
31%
27,6%
25,9%
15%
14%
10%
MONTHS
3
6
9
12
15 18
3
6
9
12
15 18
24
24
IMPROVED MUCH IMPROVED VERY MUCH IMPROVED
A clinical trial by Moers-Carpi and Sherwood (2013) assessed the effectiveness of Ellansé-S (n=10) and Ellansé-M (n=30) for the correction of moderate to severe nasolabial folds using GAIS at 3, 6, 9, 12, 18 and 24 months post-treatment.
Actual patient. Individual results may vary.
8 ELLANSÉ PRACTITIONER GUIDE
9 ELLANSÉ PRACTITIONER GUIDE
Made with FlippingBook interactive PDF creator